Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2014

01-05-2014 | Review

Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis

Authors: Shan Li, Xiamei Huang, Huizhi Zhong, Qiliu Peng, Siyuan Chen, Yantong Xie, Xue Qin, Aiping Qin

Published in: Tumor Biology | Issue 5/2014

Login to get access

Abstract

Adiponectin, as an important adipocytokine, plays a pivotal role in the regulation of insulin sensitivity and metabolism. It has been reported that circulating adiponectin levels were decreased in women with polycystic ovary syndrome (PCOS). However, the results remained inconsistent. In order to derive a more precise estimation of this relationship, a large meta-analysis was performed in this study. A comprehensive systematic electronic search was conducted in electronic databases PubMed, EMBASE, and Web of Science up to November 30, 2013. Pooled weighted mean differences (WMDs) with 95 % confidence intervals (CIs) were calculated to estimate the strength of the association. A meta-analysis technique was used to study 38 trials involving 1,944 PCOS women and 1,654 healthy controls. Overall pooled adiponectin levels in women with PCOS were significantly reduced compared with healthy controls (WMD −2.67, 95 % CI −3.22 to −2.13; P = 0.000), yet with significant heterogeneity across studies (I2 = 95.9 %, P = 0.000). In subgroup analysis by HOMA-IR ratio and total testosterone ratio, inconsistent results were presented. No single study was found to affect the overall results by sensitivity testing. Meta-regression suggested that BMI might contribute little to the heterogeneity between including studies. Cumulative meta-analysis demonstrated the reliability and stability of the meta-analysis results. No evidence of publication bias was observed. Our meta-analysis suggested that circulating adiponectin levels in women with PCOS were significantly lower than those in healthy controls, which indicated that circulating adiponectin might play a role in the development of PCOS.
Literature
1.
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis, and diagnosis. Nat Rev Endocrinol. 2011;7:219–31.CrossRefPubMed
2.
Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril. 2006;86 Suppl 1:S7–8.CrossRefPubMed
3.
Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83:1717–23.CrossRefPubMed
4.
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.CrossRefPubMedPubMedCentral
5.
Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes, and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347–63.CrossRefPubMed
6.
Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 2007;18:280–5.CrossRefPubMed
7.
Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:48–53.CrossRefPubMed
8.
Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 2011;17:741–60.CrossRefPubMed
9.
Gulcelik NE, Aral Y, Serter R, Demir Y, Culha C. Adiponectin is an independent determinant of insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22:511–5.CrossRefPubMed
10.
Gulcelik NE, Aral Y, Serter R, Koc G. Association of hypoadiponectinemia with metabolic syndrome in patients with polycystic ovary syndrome. J Natl Med Assoc. 2008;100:64–8.CrossRefPubMed
11.
O’Connor A, Phelan N, Tun TK, Boran G, Gibney J, Roche HM. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab. 2010;95:1378–85.CrossRefPubMed
12.
Sharifi F, Hajihosseini R, Mazloomi S, Amirmogaddami H, Nazem H. Decreased adiponectin levels in polycystic ovary syndrome, independent of body mass index. Metab Syndr Relat Disord. 2010;8:47–52.CrossRefPubMed
13.
Tao T, Wickham 3rd EP, Fan W, Yang J, Liu W. Distribution of adiponectin multimeric forms in Chinese women with polycystic ovary syndrome and their relation to insulin resistance. Eur J Endocrinol. 2010;163:399–406.CrossRefPubMedPubMedCentral
14.
Bohler Jr H, Mokshagundam S, Winters SJ. Adipose tissue and reproduction in women. Fertil Steril. 2010;94:795–825.CrossRefPubMed
15.
Michalakis KG, Segars JH. The role of adiponectin in reproduction: from polycystic ovary syndrome to assisted reproduction. Fertil Steril. 2010;94:1949–57.CrossRefPubMedPubMedCentral
16.
Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol. 2008;284:38–45.CrossRefPubMed
17.
Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302:179–88.CrossRefPubMed
18.
Zhang BC, Liu WJ, Che WL, Xu YW. Serum total adiponectin level and risk of cardiovascular disease in Han Chinese populations: a meta-analysis of 17 case–control studies. Clin Endocrinol (Oxf). 2012;77:370–8.CrossRef
19.
Kim DH, Kim C, Ding EL, Townsend MK, Lipsitz LA. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62:27–32.CrossRefPubMedPubMedCentral
20.
Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchon R, Luque-Ramirez M, et al. Adiponectin and resistin in PCOS: a clinical, biochemical, and molecular genetic study. Hum Reprod. 2006;21:2257–65.CrossRefPubMed
21.
Orio Jr F, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2619–23.CrossRefPubMed
22.
Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod. 2003;18:1790–6.CrossRefPubMed
23.
Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 2005;152:389–94.CrossRefPubMed
24.
Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009;15:297–307.CrossRefPubMed
25.
Li X, Huang HY, Ma D, Zhu MW. Lin JF: [correlations between adipocytokines and insulin resistance in women with polycystic ovary syndrome]. Zhonghua Yi Xue Za Zhi. 2009;89:2607–10.PubMed
26.
Pinhas-Hamiel O, Singer S, Pilpel N, Koren I, Boyko V, Hemi R, et al. Adiponectin levels in adolescent girls with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2009;71:823–7.CrossRef
27.
Wang Y. Yu P: [clinical significance and changes of serum visfatin, adiponectin, and leptin levels in patients with polycystic ovarian syndrome]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009;34:72–5.PubMed
28.
Yilmaz M, Bukan N, Demirci H, Ozturk C, Kan E, Ayvaz G, et al. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25:246–52.CrossRefPubMed
29.
Arikan S, Bahceci M, Tuzcu A, Kale E, Gokalp D. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. Gynecol Endocrinol. 2010;26:161–6.CrossRefPubMed
30.
Demirci H, Yilmaz M, Ergun MA, Yurtcu E, Bukan N, Ayvaz G. Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance, and clinical parameters. Gynecol Endocrinol. 2010;26:348–55.CrossRefPubMed
31.
Tarkun I, Dikmen E, Cetinarslan B, Canturk Z. Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome. Eur Cytokine Netw. 2010;21:272–7.PubMed
32.
Cekmez F, Cekmez Y, Pirgon O, Canpolat FE, Aydinoz S, Metin Ipcioglu O, et al. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. Eur Cytokine Netw. 2011;22:32–7.PubMed
33.
Choi JH, Rhee EJ, Kim KH, Woo HY, Lee WY, Sung KC. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol. 2011;165:789–96.CrossRefPubMed
34.
Olszanecka-Glinianowicz M, Kuglin D, Dabkowska-Huc A, Skalba P. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011;154:51–6.CrossRefPubMed
35.
Pangaribuan B, Yusuf I, Mansyur M, Wijaya A. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2011;2:235–45.CrossRefPubMedPubMedCentral
36.
Savastano S, Valentino R, Di Somma C, Orio F, Pivonello C, Passaretti F, et al. Serum 25-hydroxyvitamin D levels, phosphoprotein enriched in diabetes gene product (ped/pea-15), and leptin-to-adiponectin ratio in women with PCOS. Nutr Metab (Lond). 2011;8:84.CrossRef
37.
38.
Wickham 3rd EP, Cheang KI, Clore JN, Baillargeon JP, Nestler JE. Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome. Metabolism. 2011;60:366–72.CrossRefPubMed
39.
Yasar L, Ekin M, Gedikbasi A, Erturk AD, Savan K, Ozdemir A, et al. Serum adiponectin levels in high school girls with polycystic ovary syndrome and hyperandrogenism. J Pediatr Adolesc Gynecol. 2011;24:90–3.CrossRefPubMed
40.
Aydogdu A, Uckaya G, Tasci I, Baysan O, Tapan S, Bugan B, et al. The relationship of epicardial adipose tissue thickness to clinical and biochemical features in women with polycystic ovary syndrome. Endocr J. 2012;59:509–16.CrossRefPubMed
41.
Golbahar J, Das NM, Al-Ayadhi MA, Gumaa K. Leptin-to-adiponectin, adiponectin-to-leptin ratios, and insulin are specific and sensitive markers associated with polycystic ovary syndrome: a case–control study from Bahrain. Metab Syndr Relat Disord. 2012;10:98–102.CrossRefPubMed
42.
Mazloomi S, Sharifi F, Hajihosseini R, Kalantari S, Mazloomzadeh S. Association between hypoadiponectinemia and low serum concentrations of calcium and vitamin d in women with polycystic ovary syndrome. ISRN Endocrinol. 2012;2012:949427.CrossRefPubMedPubMedCentral
43.
Spanos N, Tziomalos K, Macut D, Koiou E, Kandaraki EA, Delkos D, et al. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss. Obes Facts. 2012;5:495–504.CrossRefPubMed
44.
Woo HY, Kim KH, Rhee EJ, Park H, Lee MK. Differences of the association of anti-mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J. 2012;59:781–90.CrossRefPubMed
45.
Kale-Gurbuz T, Akhan SE, Bastu E, Telci A, Iyibozkurt AC, Topuz S. Adiponectin, leptin and ghrelin levels in obese adolescent girls with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2013;26:27–30.CrossRefPubMed
46.
Lee H, Oh JY, Sung YA. Adipokines, insulin-like growth factor binding protein-3 levels, and insulin sensitivity in women with polycystic ovary syndrome. Korean J Intern Med. 2013;28:456–63.CrossRefPubMedPubMedCentral
47.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group. JAMA. 2000;283:2008–12.CrossRefPubMed
48.
49.
50.
51.
Li S, Liu Y, Peng Q, Xie L, Wang J, Qin X. Chewing gum reduces postoperative ileus following abdominal surgery: a meta-analysis of 17 randomized controlled trials. J Gastroenterol Hepatol. 2013;28:1122–32.CrossRefPubMed
52.
Shen W, Li T, Hu Y, Liu H, Song M. Calpain-10 genetic polymorphisms and polycystic ovary syndrome risk: a meta-analysis and meta-regression. Gene. 2013;531:426–34.CrossRefPubMed
53.
54.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMed
55.
Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol. 2002;31:88–95.CrossRefPubMed
56.
Panidis D, Farmakiotis D, Rousso D, Koliakos G, Kaltsas T, Krassas G. Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test. Fertil Steril. 2005;83:232–4.CrossRefPubMed
57.
Lecke SB, Mattei F, Morsch DM, Spritzer PM. Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. Fertil Steril. 2011;95:2044–9.CrossRefPubMed
58.
Safar FH, Mojiminiyi OA, Al-Rumaih HM, Diejomaoh MF. Computational methods are significant determinants of the associations and definitions of insulin resistance using the homeostasis model assessment in women of reproductive age. Clin Chem. 2011;57:279–85.CrossRefPubMed
59.
Pepene CE. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012;76:119–25.CrossRef
60.
Singh S, Akhtar N, Ahmad J. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case–control study. Diabetes Metab Syndr. 2012;6:207–11.CrossRefPubMed
61.
Lecke SB, Morsch DM, Spritzer PM: association between adipose tissue expression and serum levels of leptin and adiponectin in women with polycystic ovary syndrome. Genet Mol Res 2013; 12.
62.
Lecke SB, Morsch DM, Spritzer PM. Association between adipose tissue expression and serum levels of leptin and adiponectin in women with polycystic ovary syndrome. Genet Mol Res. 2013;12:4292–6.CrossRefPubMed
63.
Jensterle M, Weber M, Pfeifer M, Prezelj J, Pfutzner A, Janez A. Assessment of insulin resistance in young women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2008;102:137–40.CrossRefPubMed
64.
Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:2670–8.CrossRefPubMed
65.
Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol. 2007;156:263–9.CrossRefPubMed
66.
Lewandowski KC, Szosland K, O’Callaghan C, Tan BK, Randeva HS, Lewinski A. Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices. Mol Genet Metab. 2005;85:61–9.CrossRefPubMed
67.
Aigner E, Bachofner N, Klein K, De Geyter C, Hohla F, Patsch W, et al. Retinol-binding protein 4 in polycystic ovary syndrome–association with steroid hormones and response to pioglitazone treatment. J Clin Endocrinol Metab. 2009;94:1229–35.CrossRefPubMed
68.
Chang CY, Chen MJ, Yang WS, Yeh CY, Ho HN, Chen SU, et al. Hypoadiponectinemia: a useful marker of dyslipidemia in women with polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2012;51:583–90.CrossRefPubMed
69.
Tao T, Xu B, Liu W. Ovarian HMW adiponectin is associated with folliculogenesis in women with polycystic ovary syndrome. Reprod Biol Endocrinol. 2013;11:99.CrossRefPubMedPubMedCentral
70.
Panidis D, Kourtis A, Kukuvitis A, Farmakiotis D, Xita N, Georgiou I, et al. Association of the t45g polymorphism in exon 2 of the adiponectin gene with polycystic ovary syndrome: role of delta4-androstenedione. Hum Reprod. 2004;19:1728–33.CrossRefPubMed
71.
Haap M, Machicao F, Stefan N, Thamer C, Tschritter O, Schnuck F, et al. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2005;113:275–81.CrossRefPubMed
72.
Zhang N, Shi YH, Hao CF, Gu HF, Li Y, Zhao YR, et al. Association of +45g15g(t/g) and +276(g/t) polymorphisms in the adipoq gene with polycystic ovary syndrome among Han Chinese women. Eur J Endocrinol. 2008;158:255–60.CrossRefPubMed
73.
Lauria PB, Del Puerto HL, Reis AM, Candido AL, Reis FM, Tao T, et al. Low plasma atrial natriuretic peptide: a new piece in the puzzle of polycystic ovary syndrome ovarian HMW adiponectin is associated with folliculogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:4882–9.CrossRefPubMed
74.
Glintborg D, Frystyk J, Hojlund K, Andersen KK, Henriksen JE, Hermann AP, et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2008;68:165–74.
75.
Barber TM, Hazell M, Christodoulides C, Golding SJ, Alvey C, Burling K, et al. Serum levels of retinol-binding protein 4 and adiponectin in women with polycystic ovary syndrome: associations with visceral fat but no evidence for fat mass-independent effects on pathogenesis in this condition. J Clin Endocrinol Metab. 2008;93:2859–65.CrossRefPubMed
76.
Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrom V, Flyvbjerg A, et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin, and body composition in hirsute PCOS patients and controls. Eur J Endocrinol. 2006;155:337–45.CrossRefPubMed
77.
Ducluzeau PH, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M, et al. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:3626–31.CrossRefPubMed
78.
Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Upregulation of adiponectin receptor 1 and 2 MRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome. Diabetologia. 2006;49:2723–8.CrossRefPubMed
79.
Aydogdu A, Tasci I, Tapan S, Sonmez A, Aydogan U, Akbulut H, et al. Women with polycystic ovary syndrome have increased plasma chitotriosidase activity: a pathophysiological link between inflammation and impaired insulin sensitivity? Exp Clin Endocrinol Diabetes. 2012;120:261–5.CrossRefPubMed
80.
Orio Jr F, Palomba S, Cascella T, Di Biase S, Labella D, Russo T, et al. Lack of an association between peroxisome proliferator-activated receptor-gamma gene pro12ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:5110–5.CrossRefPubMed
81.
Beckman JA, Goldfine AB, Dunaif A, Gerhard-Herman M, Creager MA. Endothelial function varies according to insulin resistance disease type. Diabetes Care. 2007;30:1226–32.CrossRefPubMed
82.
Moran LJ, Noakes M, Clifton PM, Wittert GA, Belobrajdic DP, Norman RJ. C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:2944–51.CrossRefPubMed
83.
Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab. 2007;92:4609–14.CrossRefPubMed
84.
Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry RR. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril. 2008;89:1200–8.CrossRefPubMed
85.
Thomann R, Rossinelli N, Keller U, Tirri BF, De Geyter C, Ruiz J, et al. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24:199–206.CrossRefPubMed
86.
Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2009;94:469–76.CrossRefPubMed
87.
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.CrossRefPubMed
88.
Brassard M, AinMelk Y, Baillargeon JP. Basic infertility including polycystic ovary syndrome. Med Clin North Am. 2008;92:1163–92. xi.CrossRefPubMed
89.
Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51:1884–8.CrossRefPubMed
90.
Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.CrossRefPubMed
91.
Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep. 2003;3:207–13.CrossRefPubMed
Metadata
Title
Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis
Authors
Shan Li
Xiamei Huang
Huizhi Zhong
Qiliu Peng
Siyuan Chen
Yantong Xie
Xue Qin
Aiping Qin
Publication date
01-05-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1595-0

Other articles of this Issue 5/2014

Tumor Biology 5/2014 Go to the issue

Research Article

INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells

Research Article

Clinicopathologic factors predicting outcomes in patients with gastrointestinal stromal tumors of the rectum and colon

Research Article

Loss of CSMD1 or 2 may contribute to the poor prognosis of colorectal cancer patients

Research Article

Bufalin inhibited the growth of human osteosarcoma MG-63 cells via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway

Research Article

Clinicopathological and prognostic significance of hypoxia-inducible factor-1α in esophageal squamous cell carcinoma: a meta-analysis

Research Article

The effect of CYP1A1 and CYP1A2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits